Cambrex

Cambrex Corporation (NYSE:CBM) provides products and services to accelerate the development and commercialization of branded and generic small molecule therapeutics. Cambrex supports its customers worldwide with R&D and cGMP manufacturing facilities in the US and Europe, an excellent regulatory compliance record and strong expertise in various chemical technologies. Pharmaceutical Products & Services Cambrex has built a comprehensive platform of chemical technologies for the synthesis of small molecule active pharmaceutical ingredients (APIs). We have extensive experience developing drug substances from early stage through clinical development, up to launch and commercial supply – from grams to tons. Cambrex has a broad range of services, which include: route selection, process development, analytical development, process scale-up, safety assessments and optimization. Our core technologies and offerings include: Highly Potent & Cytotoxic Compounds, High Energy, Hydrogenation, Biocatalysis/Biotransformation, Chiral Synthesis, Controlled Substances, Nitration and Polymeric Drug Delivery, including Taste Masking. Generic APIs For generic drug companies, Cambrex supplies more than 70 APIs (including controlled substances) for pain management, cardiovascular, gastrointestinal, central nervous system, endocrine and respiratory indications. Cambrex manufactures these products using complex chemistry and technical expertise while maintaining its long-standing reputation of quality and reliability. We work with generic drug companies well in advance of drug patent expiration, provide a non-infringing process and file a Drug Master File (DMF) for the generic active pharmaceutical ingredients.

Contact Details: ONE MEADOWLANDS PLAZA, EAST RUTHERFORD New Jersey 07073 United States of America Tel: 201 804 3000 Fax: Email: pharma@cambrex.com WWW: www.cambrex.com/

Loading...

Recent Publications by Cambrex:
Kinetic characterization and in vitro toxicity evaluation of a luciferase less susceptible to HPV chemical inhibition. Enzyme-based in vitro toxicity assays are often susceptible to inhibition...	27th December, 2006	Cambrex North Brunswick, 661 Highway One, North Brunswick, NJ 08902, USA.	Toxicol In Vitro. 2006 Dec;20(8):1537-47. Epub 2006 Jul 12. DOI Direct Link
Differentiating primary human cells in rapid-throughput discovery applications. Primary cultures of human cells provide an increasingly important...	9th December, 2006	Cambrex Corporation, Baltimore, MD, USA.	Methods Mol Biol. 2007;356:121-8.
Creating a mutant luciferase resistant to HPV chemical inhibition by random mutagenesis and colony-level screening. Firefly luciferase covers a wide range of applications. One common usage...	31st August, 2006	Cambrex North Brunswick, North Brunswick, NJ 08902, USA.	Luminescence. 2006 May-Jun;21(3):135-42. DOI Direct Link

Press Releases on Cambrex:
Cambrex Reports Third Quarter 2009 Results	3rd November, 2009	Cambrex Corporation	-- Net income was $3.0 million compared with Net income of $2.8 million for the third quarter of 2008. Third Quarter 2009 Operating Results Third quarter 2009 sales of $57.8 million
Cambrex to Announce Third Quarter 2009 Financial Results on November 3, 2009	27th October, 2009	Cambrex Corporation	EAST RUTHERFORD, N.J., Oct. 27 /PRNewswire-FirstCall/ -- Cambrex Corporation (NYSE: CBM) announced that third quarter 2009 financial results will be released on Tuesday, November 3, 2009 after the
Cambrex Continuous-Flow Microwave-Assisted Organic Synthesis Technology Wins 2009 Silver Innovation Award	20th October, 2009	Cambrex Corporation	EAST RUTHERFORD, N.J., Oct. 20 /PRNewswire-FirstCall/ -- Cambrex Corporation (NYSE: CBM) announced today that it won the Silver Innovation Award at the 2009 CPhI Event for its Continuous-Flow
Cambrex Reports First Quarter 2009 Results	5th May, 2009	Cambrex Corporation	CAMBREX CORPORATION Statement of Profit and Loss For the Quarters Ended March 31, 2009 and 2008
Cambrex to Announce First Quarter 2009 Financial Results on May 5, 2009	29th April, 2009	Cambrex Corporation	EAST RUTHERFORD, N.J., April 29 /PRNewswire-FirstCall/ -- Cambrex Corporation (NYSE: CBM) announced that first quarter 2009 financial results will be released on Tuesday, May 5, 2009 after the market

BioNews Results for Cambrex:
Cambrex sales rise in Q3 despite 'challenging environment'	Pharmafocus:  Nov 9 2009 8:18AM Matching: cambrex
Cambrex sales rise in Q3 despite 'challenging environment'	Pharmafocus:  Nov 9 2009 7:33AM Matching: cambrex
Cambrex Reports Third Quarter 2009 Results	PR Newswire:  Nov 8 2009 5:57PM Matching: cambrex
Cambrex Reports Third Quarter 2009 Results	Pharmacy Choice:  Nov 4 2009 8:16AM Matching: cambrex
Cambrex Reports Third Quarter 2009 Results	Genetic Engineering News:  Nov 4 2009 5:46AM Matching: cambrex
Promote your company here: BioNewsCast - Press Release Distribution	→View more Cambrex news.

Cambrex Patents:
US Patent No.	Title
7585644	Mycopolasma detecting methods and materials
6586449	Nicotine-containing, controlled release composition and method
6828336	Nicotine-containing, controlled release composition and method
6849426	Methods and reagents for detecting endotoxin
6870065	Bifunctional boronic compound complexing reagents and complexes
→View more Cambrex patents.

Cambrex (CBM) Financial information Links from Barchart
CBM Quote from from Barchart.com
CBM Chart from from Barchart.com
CBM Profile from from Barchart.com
CBM Opinion from from Barchart.com
→View more Cambrex finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 527 times since April 2007, the link to the organisation's website has been followed 111 times

Recent Search Terms used to find this page: enzyme cambrex | .

Search for more companies in EAST RUTHERFORD

Search for more companies in New Jersey

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Cambrex